The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 17, 2025

Filed:

Aug. 26, 2019
Applicant:

Hangzhou Converd Co., Ltd., Zhejiang, CN;

Inventors:

Fang Hu, Zhejiang, CN;

Can Chen, Zhejiang, CN;

Lin Xiao, Zhejiang, CN;

Jin Fu, Zhejiang, CN;

Rong Zhang, Zhejiang, CN;

Jinlu Cai, Zhejiang, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 40/31 (2025.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/42 (2025.01); A61K 47/68 (2017.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
A61K 47/6891 (2017.08); A61K 35/17 (2013.01); A61K 38/1774 (2013.01); A61K 39/0011 (2013.01); A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 48/0058 (2013.01); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 5/0646 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/50 (2023.05); A61K 2239/59 (2023.05);
Abstract

Provided are therapeutic agent including nucleic acid and CAR-modified immune cell and the use thereof. The therapeutic agent comprises first composition and second composition, the first composition comprises a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and/or a cancer cell; the labeling polypeptide has an extracellular antigen determining region, a spacer portion, and a transmembrane portion that are operatively linked, which can be expressed to form modification on the surface of the tumor cell and/or cancer cell; the extracellular antigen determining region comprises one or more epitope polypeptides; wherein, amino acid sequences of proteins on cell membrane or secreted proteins of mammal do not comprise the epitope polypeptide amino acid sequence in the natural state; the second composition comprises chimeric antigen receptor modified immune cell which specifically recognize and bind to the extracellular antigen determining region. The therapeutic agent achieves synergistic therapeutic effect.


Find Patent Forward Citations

Hu, Fang. (2025). Therapeutic agents comprising nucleic acids and car-modified immune cells, and uses thereof (U.S. Patent No. 12329826). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12329826

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…